Rodaris Pharmaceuticals Limited

University College London

Rademacher Group Limited

Other

Hugo Norberto Caro

Thomas William Rademacher

Manuel Martin-Lomas

Irene Francois

Thomas W Rademacher

Graham A Rook

Janice Taverne

John Playfair

Nadeem Sheikh

Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. In particular, the compounds are based on the 1,6 linkage of a sugar residue and a cyclitol.

Compounds and their uses

Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. Preferred compounds of the invention are based on the substituted cyclitols, such as the chiro-inositol derivative pinitol (3-O-methyl-chiro-inositol).

Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. Preferred compounds of the invention are based on the substituted cyclitols, and in particular cyclitols linked to a sugar moiety where the molecule is substituted with a negatively charged group such as phosphate.

Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. Preferred compounds of the invention are based on the substituted cyclitols, and in particular, the compounds are based on the 1,6 linkage of two or more sugar residues to a cyclitol.

The present invention provides for an isolated A-type substance having a structure identical to an A-type substance obtained from human liver or placenta, which is a cyclical containing carbohydrate comprising Zn,and related compositions.

Cyclitol Containing carbohydrates from human tissue which regulate lipogenic activity

The present invention provides for an isolated P-type substance having a structure identical to a P-type substance obtained from human liver or placenta, which is a cyclitol containing carbohydrate comprising Mn,and Zn,and related compositions.

Cyclitol containing carbohydrates from human tissue which regulate glycogen metabolism

Hormone and growth factor phosphoglycokine mimetics from mycobacterium

The present invention is directed to the use of glycosidase inhibitors for inhibiting the conversion of a pro-toxin to a toxin by a glycosidase enzyme. In particular, the present invention relates to the use of glycosidase inhibitors for the treatment of malaria, endotoxic shock or septic shock.

Growing community of inventors

London, United Kingdom

Hugo Norberto Caro